enow.com Web Search

  1. Ads

    related to: latest developments in schizophrenia treatment in atlanta area code

Search results

  1. Results from the WOW.Com Content Network
  2. FDA approves new type of schizophrenia drug - AOL

    www.aol.com/news/fda-approves-type-schizophrenia...

    The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

  3. Skyland Trail - Wikipedia

    en.wikipedia.org/wiki/Skyland_Trail

    Skyland Trail is a private, non-profit organization in Atlanta, Georgia offering treatment to adults ages 18 and older and adolescents ages 14 to 17 with mental illnesses. Skyland Trail specializes in treating adults and adolescents with bipolar disorder , schizophrenia , depression , and anxiety disorders. [ 1 ]

  4. FDA Approves the First New Schizophrenia Drug in Decades - AOL

    www.aol.com/fda-approves-first-schizophrenia...

    N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

  5. Brilaroxazine - Wikipedia

    en.wikipedia.org/wiki/Brilaroxazine

    Brilaroxazine (developmental code name RP5063), also known as oxaripiprazole, [1] [2] is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of neuropsychiatric and inflammatory disorders. [3] [5] [6] [7] It has currently completed the first of two phase III clinical trials for ...

  6. Roluperidone - Wikipedia

    en.wikipedia.org/wiki/Roluperidone

    Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.

  7. Neurocrine halts development of schizophrenia drug as ... - AOL

    www.aol.com/news/neurocrine-halts-development...

    In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.

  1. Ads

    related to: latest developments in schizophrenia treatment in atlanta area code